Back

PCSK9 inhibition: what do we know from clinical trials?

27 August 2017 (17:42 - 18:00)
Organised by:
Congress Presentation Part of: PCSK9: Beyond lipid - lowering effects? Endothelial function ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

3 More presentations in this session

Presentation thumbnail
State of the Art: PCSK9 - Beyond lipid-lowering effects?
Professor U. Landmesser (Berlin, DE)
Slides Video
Presentation thumbnail
PCSK9 beyond its role in cholesterol homeostasis: co-activator of platelet function
Assistant Professor M. Camera (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Serum PCSK9 in relation to coronary near-infrared spectroscopy-derived lipid core burden index and long-term cardiovascular outcome [ATHEROREMO-NIRS substudy].
Miss S. Anroedh (Rotterdam, NL)
Abstract

Access the full session

Session thumbnail
PCSK9: Beyond lipid - lowering effects?

The Event

Event poster

ESC Congress 2017

27 August 2017 17:42 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Webinar
How to treat patients with borderline dyslipidemia
8 February 2023
thumbnail
Congress Presentation
Inclisiran reduces expression of Toll-like receptor-4 on circulating monocytes
28 August 2023
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources